ARTICLE | Clinical News
Serlopitant: Ph II AUBURN (MTI-104) started
January 12, 2017 10:16 PM UTC
Menlo began the double-blind, placebo-controlled, U.S. Phase II AUBURN (MTI-104) trial to evaluate oral serlopitant in about 150 patients. Menlo has exclusive, worldwide rights to serlopitant from Mer...